(R)-2-(toluene-4-sulfonyloxymethyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-2-(toluene-4-sulfonyloxymethyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one
• 英文别名: [(2R)-8-oxo-2,3,8,9-tetrahydro-7H-[1,4]dioxino[2,3-e]indol-2-yl]methyl 4-methylbenzenesulfonate；[(2R)-8-oxo-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-2-yl]methyl 4-methylbenzenesulfonate
• 化学式: C₁₈H₁₇NO₆S
• 分子量: 375.402
• InChiKey: NEIMQDAUWLGLNZ-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  99.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-2-(toluene-4-sulfonyloxymethyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one 以100的产率得到(S)-2-(benzylamino-methyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino(2,3-e]indol-8-one
  参考文献：
  名称：

  Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones

  摘要：

  提供了制备取代氨甲基2,3,8,9-四氢-7H-1,4-二氧杂环[2.3-e]吲哚-8-酮（式（A）中的变量n，R和R3如本文所述）的工艺和中间体。这些化合物例如作为多巴胺受体激动剂是有用的。

  公开号：

  US08466296B2
• 作为产物：
  描述：

  2-甲氧基-5-硝基苯酚 在 palladium 10% on activated carbon 吡啶 、 盐酸 、 1,4-环己二烯 、 potassium tert-butylate 、 四丁基溴化铵 、 水 、 氢气 、 碳酸氢钠 、 potassium carbonate 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 110.0 ℃ 、344.75 kPa 条件下， 反应 45.0h， 生成 (R)-2-(toluene-4-sulfonyloxymethyl)-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-one
  参考文献：
  名称：

  WO2008/118935

  摘要：

  公开号：

文献信息

• Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino\x9b2 3-E!-indol-8-ones and
  申请人：American Home Products Corporation

  公开号：US05756532A1

  公开（公告）日：1998-05-26

  The compounds of formula I: ##STR1## wherein R.sup.1 and R.sup.2 are, independently, hydrogen, alkyl, phenyl or benzyl; or R.sup.1 and R.sup.2, taken together, are benzylidene optionally substituted with R.sup.3 as defined below or alkylidene, or R.sup.1 and R.sup.2, taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R.sup.3 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; R.sup.4 is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R.sup.3 as defined above, phenoxy optionally substituted with R.sup.3 as defined above, naphthyl optionally substituted with R.sup.3 as defined above or naphthyloxy optionally substituted with R.sup.3 as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyril, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R.sup.3 as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.

  式I的化合物：其中R.sup.1和R.sup.2分别是氢、烷基、苯基或苄基；或R.sup.1和R.sup.2一起是苄基亦可选择性地用如下定义的R.sup.3取代或烷基亦可选择性地用如下定义的R.sup.3取代，或R.sup.1和R.sup.2与它们附着的碳一起形成一个羰基或环烷基；R.sup.3是氢、羟基、卤素、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基氧基、烷酰氧基、氨基、单烷基或双烷基氨基、烷酰胺基或烷磺酰胺基；R.sup.4是氢或烷基；m是整数0、1或2；n是整数0至6之间的整数；Z是氢、羟基、烷基、烯基、炔基、烷氧基、环烷基、多环烷基、苯基亦可选择性地用如上定义的R.sup.3取代、苯氧基亦可选择性地用如上定义的R.sup.3取代、萘基亦可选择性地用如上定义的R.sup.3取代或萘氧基亦可选择性地用如上定义的R.sup.3取代、杂环芳基或杂环芳氧基，其中杂环芳基或杂环芳氧基的杂环环由噻吩、呋喃、吡啶、吡嗪、嘧啶、吲哚、吲唑、咪唑、色苷、香豆素、喹啉、苯并异噁唑、苯并噁唑、吡唑、吡咯、噻唑、噁唑或异噁唑组成，并且该杂环环可以选择性地用如上定义的R.sup.3取代；或者其药学上可接受的盐，用于治疗多巴胺系统疾病。
• Azaheterocyclymethyl derivatives of 2,3,8,9-tetrahydro-7h-1,4-dioxino
  申请人：American Home Products Corporation

  公开号：US05869490A1

  公开（公告）日：1999-02-09

  The compounds of formula I: ##STR1## wherein X is H.sub.2 or O; R.sup.1 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; Z is defined by ##STR2## wherein R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined in the specification; or a pharmaceutically acceptable salt thereof, are useful for the treatment of brain dopamine dysregulation.

  化合物的化学式I为：##STR1## 其中X为H.sub.2或O；R.sup.1为氢、羟基、卤素、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基烷氧基、烷酰氧基、氨基、单烷基或双烷基氨基、烷基酰胺基或烷基磺酰胺基；Z由##STR2##定义，其中R.sup.2、R.sup.3、R.sup.4、R.sup.5和R.sup.6如规范中定义；或其药学上可接受的盐，用于治疗大脑多巴胺失调。
• Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia
  作者：Yinfa Yan、Ping Zhou、David P. Rotella、Rolf Feenstra、Chris G. Kruse、Jan-Hendrik Reinders、Martina van der Neut、Margaret Lai、Jean Zhang、Dianne M. Kowal、Tikva Carrick、Karen L. Marquis、Mark H. Pausch、Albert J. Robichaud

  DOI：10.1016/j.bmcl.2010.02.105

  日期：2010.5

  inhibitor pharmacophore when combined with certain amines. This fragment was coupled with selected D2 ligands to prepare a series of dual acting compounds with attractive in vitro profiles as dopamine D2 partial agonists and serotonin reuptake inhibitors. Structure–activity studies revealed that the linker plays a key role in contributing to D2 affinity, function, and SRI activity.

  当与某些胺结合时，发现二氢喹啉酮部分是有效的5-羟色胺再摄取抑制剂药效基团。该片段与选择的D 2配体偶联以制备一系列具有有吸引力的体外作用的双作用化合物，如多巴胺D 2部分激动剂和5-羟色胺再摄取抑制剂。结构活性研究表明，该接头在促进D 2亲和力，功能和SRI活性中起关键作用。
• Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones
  申请人：Wang Zhe-qing

  公开号：US08466296B2

  公开（公告）日：2013-06-18

  Processes and intermediates are provided for the preparation of substituted aminomethyl 2,3,8,9-tetrahydiO-7H-1,4-dioxino[2.3-e]indo]-8-ones of the Formula (A) wherein the variables n, R and R3 are as described herein. Such compounds are useful, for example, as dopamine receptor agonists.

  提供了制备取代氨甲基2,3,8,9-四氢-7H-1,4-二氧杂环[2.3-e]吲哚-8-酮（式（A）中的变量n，R和R3如本文所述）的工艺和中间体。这些化合物例如作为多巴胺受体激动剂是有用的。
• Aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino-\x9b2,3-e!-indol-8-ones and
  申请人：American Home Products Corporation

  公开号：US05962465A1

  公开（公告）日：1999-10-05

  The compounds of formula I: ##STR1## wherein R.sup.1 and R.sup.2 are, independently, hydrogen, alkyl, phenyl or benzyl; or R.sup.1 and R.sup.2, taken together, are benzylidene optionally substituted with R.sup.3 as defined below or alkylidene, or R.sup.1 and R.sup.2, taken together with the carbon to which they are attached, form a carbonyl moiety or a cycloalkyl group; R.sup.3 is hydrogen, hydroxy, halo, trifluoromethyl, trifluoromethoxy, alkyl, alkoxy, aralkoxy, alkanoyloxy, amino, mono- or di-alkylamino, alkanamido or alkanesulfonamido; R.sup.4 is hydrogen or alkyl; m is an integer 0, 1 or 2; n is an integer from 0 to 6, inclusive; Z is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, polycyclo-alkyl, phenyl optionally substituted with R.sup.3 as defined above, phenoxy optionally substituted with R.sup.3 as defined above, naphthyl optionally substituted with R.sup.3 as defined above or naphthyloxy optionally substituted with R.sup.3 as defined above, heteroaryl or heteroaryloxy, in which the heterocyclic ring of the heteroaryl or heteroaryloxy group is selected from thiophene, furan, pyridine, pyrazine, pyrimidine, indole, indazole, imidazole, chroman, coumarin, carbostyril, quinoline, benzisoxazole, benzoxazole, pyrazole, pyrrole, thiazole, oxazole, or isoxazole and the heterocyclic ring is optionally substituted by R.sup.3 as defined above; or a pharmaceutically acceptable salt thereof, are useful in treating disorders of the dopaminergic system.

  化学式为I的化合物：##STR1## 其中R.sup.1和R.sup.2分别为氢、烷基、苯基或苄基；或R.sup.1和R.sup.2连在一起，是苄基亚甲基，可选地用下面定义的R.sup.3取代，或烷基亚甲基，或R.sup.1和R.sup.2与它们连接的碳形成羰基基团或环烷基；R.sup.3为氢、羟基、卤素、三氟甲基、三氟甲氧基、烷基、烷氧基、芳基氧基、烷酰氧基、氨基、单烷基或二烷基氨基、烷基酰胺或烷基磺酰胺；R.sup.4为氢或烷基；m为0、1或2的整数；n为0到6的整数，包括0和6；Z为氢、羟基、烷基、烯基、炔基、烷氧基、环烷基、多环环烷基、苯基（可选地用上述定义的R.sup.3取代）、苯氧基（可选地用上述定义的R.sup.3取代）、萘基（可选地用上述定义的R.sup.3取代）或萘氧基（可选地用上述定义的R.sup.3取代）、杂环芳基或杂环芳基氧基，其中杂环芳基或杂环芳基氧基的杂环环选自噻吩、呋喃、吡啶、吡嗪、嘧啶、吲哚、吲唑、咪唑、色甘醇、香豆素、喹啉、苯并异噁唑、苯并噁唑、吡唑、吡咯、噻唑、噁唑或异噁唑，且杂环环可选地由上述定义的R.sup.3取代；或其药学上可接受的盐，适用于治疗多巴胺系统疾病。